Feasibility of Polyendocrine Metabolic Ovarian Syndrome Screening in the Workplace. A Pilot Cohort Study

<jats:p>Polyendocrine Metabolic Ovarian Syndrome (PMOS) is the most common endocrine disorder in working women. Workplace screening could contribute to the early diagnosis and treatment of this chronic condition. Women who participated in a 2022 health food promotion campaign were interviewed about PMOS symptoms during their in-office medical examination. Suspected cases were offered further evaluation. 28 of the 1,170 women examined had symptoms of suspected PMOS. By 2023, 21 of these diagnoses had been confirmed. The prevalence of newly diagnosed PMOS was 2.7% (CI95% 1.7; 4.2). The predictive value of the clinical suspicion of PMOS was 75% (CI95% 55.1; 89.3). Female workers with PMOS had a significantly higher frequency of eating disorders than their pre-menopausal colleagues; higher body mass index values (26.9±5.2 vs. 23.3±4.3), higher glycemia (120.5±49.3 vs. 81.7±25.2, p&amp;lt;0.001) and higher cholesterol values (232.7±24.5 vs. 181.6±37.7, p&amp;lt;0.001). PMOS patients also had lower sleep quality, higher anxiety and higher depression symptom scores than other workers of childbearing age. In conclusion, with a short interview during mandatory medical examinations, the occupational physician can make a significant contribution to the diagnosis of PMOS, thereby improving the quality of life of women and reducing damage to their health.</jats:p>